Orlistat binds to the active site of gastric and pancreatic lipases, blocking the breakdown of triglycerides into absorbable free fatty acids and monoglycerides. This action occurs locally in the gastrointestinal tract, which limits its systemic absorption and minimizes systemic adverse effects.
